Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

NATCOPHARM is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 5.586000
forwardPE 24.898518
debtToEquity 3.670000
earningsGrowth 0.053000
revenueGrowth 0.140000
grossMargins 0.844270
operatingMargins 0.368390
trailingEps 105.290000
forwardEps 41.270000

A current ratio of 5.586 for NATCOPHARM implies that the company has ample liquidity to meet its short-term debts. NATCOPHARM's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
NATCOPHARM's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
Positive gross and operating margins for NATCOPHARM highlight the company's profitability. These metrics reflect NATCOPHARM's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
NATCO Pharma Limited's forward EPS being less than trailing EPS suggests the company may see a drop in profitability this year. This signals potential financial challenges and a less optimistic outlook for earnings growth.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

Over time, price projections for NATCO Pharma Limited have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for NATCO Pharma Limited's continued growth.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


17 NATCO Pharma Limited stock sales were completed, with market price of 1383.602933995864.2 transactions to buy NATCOPHARM took place, with market price at 851.625 per share.The recent trend of more purchases than sales at NATCOPHARM's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


A recent sell bias from analysts toward NATCO Pharma Limited suggests caution, but investors should look beyond this sentiment. It's advisable to consider a broad range of market indicators to make well-informed decisions, ensuring a deeper understanding of the stock's potential and market behavior.